Acyl-Enzymes as Thrombolytic Agents in a Rabbit Model of Venous Thrombosis

Summary

A derivative of human lys-plasmin in which the active site has been reversibly acylated (BRL 26920; p-anisoyl human lys-plasmin) has been examined as a fibrinolytic agent in a previously described rabbit model of venous thrombosis and shown to be significantly more active and less fibrinogenolytic than free plasmin. A p-anisoylated derivative of a streptokinase (SK)-activated plasmin preparation was significantly less fibrinogenolytic in vivo than the non-acylated enzyme. Acylation increased the fibrinolytic activity of preparations of SK-plasmin activator complexes. BRL 26921, the active site anisoylated derivative of the primary 2-chain SK-plasminogen complex was the most potent fibrinolytic agent studied. SK-Val₄₄₂-plasminogen complexes, free or acylated, were biologically inactive in this model and confirm the essential nature of fibrin binding processes for effective thrombolysis in vivo.

Key words

Thrombolysis - Plasmin - Acyl-plasmin - Streptokinase-plasmin - Acyl-streptokinase-plasmin(ogen) complexes

• References

• 1 Smith RAG, Dupe RJ, English PD, Green J. Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy. Nature 1981; 290: 505-508
• 2 Dupe RJ, English PD, Smith RAG, Green J. The evaluation of plasmin and streptokinase activator complexes in a new rabbit model of venous thrombosis. Thromb Haemostas 1981; 46: 528-534
• 3 Smith RAG. Eur Patent Appl. 1980 No 9879.
• 4 Sottrup-Jensen L, Claeys H, Zajdel M, Petersen TE, Magnusson S. The primary structure of human plasminogen: isolation of two lysine-binding fragments and one “mini”-plasminogen (MW 38,000) by elastase-catalysed specific limited proteolysis. In: Progress in chemical fibrinolysis and thrombolysis. Davidson JF. et al (Eds). Raven Press; 1978: 191-209
• 5 Weber K, Pringle JR, Osbom M. In: Methods in enzymology. Hirs CHW, Timasheff SW. (Eds). Vol. 26 Academic Press; 1972: 5-27
• 6 McClintock DK, Bell PH. The mechanism of activation of human plasminogen by streptokinase. Biochem Biophys Res Commun 1971; 43: 694-702
• 7 Powell JR, Castellino FJ. Activation of human neo-plasminogen-Val₄₄₂ by urokinase and streptokinase and a kinetic characterisation of neo-plasmin-Val₄₄₂ . J Biol Chem 1980; 255: 5329-5335
• 8 Summaria L, Arzadon L, Bemabe P, Robbins KC. The interaction of streptokinase with human, cat, dog and rabbit plasminogen. J Biol Chem 1974; 249: 4760-4769
• 9 Markus G, Evers JL, Hobika GH. Activator activities of the transient forms of the human plasminogen-streptokinase complex during its proteolytic conversion to the stable activator complex. J Biol Chem 1976; 251: 6495-6504
• 10 Summaria L, Boreisha IG, Arzadon L, Robbins KC. The dissolution of human cross-linked plasma fibrin clots by the equimolar human plasmin-derived light (B) chain streptokinase complex. The acceleration of clot lysis by pretreatment of fibrin clots with the light (B) chain. Thromb Res 1977; 11: 377-389
• 11 National Institutes of Health Concensus Development Conference Summary. Thrombolytic therapy in thrombosis. Ann Intern Med 1980; 93: 141-144
• 12 Matsuo O, Rijken DC, Collen D. Comparison of the relative fibrinogenolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Thromb Haemostas 1981; 45: 225-229
• 13 Matsuo O, Rijken DC, Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolism. Nature 1981; 291: 590-591
• 14 Matsuo O, Collen D, Verstraete M. On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinaseplasminogen complex (BRL 26921). Thromb Res 1981; 24: 347-358